26 results about "Nerve Diseases" patented technology

The present technology related to a genus of compounds which are prodrugs of arimoclomol. The present technology further relates to compositions comprising the same and methods of treating neurological diseases and disorders by administering said compounds.

The application discloses a cistema brain-computer interface-minimally invasive whole brain nerve signal acquisition and closed-loop control system based on a cerebrospinal fluid channel and a method thereof. The system comprises a flexible cistema interface array, an ultra-wideband wireless energy and data synchronous transmission module, a nerve signal analysis and decoding module, a self-adaptive closed-loop control module and a system integrated control platform. The flexible cistema interface array is implanted in a cerebrospinal fluid cavity in a minimally invasive manner to acquire multi-brain region nerve signals; and the ultra-wideband transmission module realizes energy supply and high-speed bidirectional communication between an implanted body and an extracorporeal device. The application solves the problems of a large trauma, limited coverage and poor signal quality of an existing invasive interface, has the advantages of minimally invasive, wide area coverage, high signal quality and good integration, and is suitable for diagnosis and treatment of neurological diseases such as epilepsy suppression and post-stroke motor function reconstruction.

Provided herein are antibodies and antigen-binding domains that specifically bind to human CD98 and their use in, for example, transport across the blood brain barrier (BBB). Among others, also provided herein are conjugates comprising these anti-CD98 antibodies and antigen-binding fragments, such as the conjugates with GLP-1R agonists, and their uses in, for example, treating or preventing neurological diseases or disorders and / or metabolic diseases or disorders.

The present invention relates to compositions and methods of GDNF fusion polypeptides, wherein the GDNF fusion polypeptides include an Fc domain, an albumin-binding peptide, a fibronectin domain, or a human serum albumin, joined to a GDNF variant either directly or by the way of a linker. The GDNF fusion polypeptides may used to treat metabolic diseases, such as obesity and Type-1 and Type-2 diabetes, and neurological diseases, such as Amyotrophic lateral sclerosis (ALS) and Parkinson's disease.

Combination therapies comprising oxytocin and gonadotropin releasing hormone are provided. The combinations can be used to treat aging-related neurological diseases or disorders. In addition, downstream effectors of OXT-GnRH combination, including hypothalamic stem / progenitor cells-derived EVs and vesicles containing or loaded with PTMS, can be used to treat aging-related neurological diseases or disorders.

The present invention addresses the problem of providing an agent for preventing or treating amyotrophic lateral sclerosis (ALS), Parkinson's disease (PD), Huntington's disease (HD), spinocerebellar ataxia (SCA), aging-related degenerative or neurological disease, brain aging, or diseases associated with brain aging, as well as a more stable antibody that exhibits an effect of preventing or treating these diseases, Alzheimer's disease (AD), or frontotemporal lobar degeneration (FTLD). A human monoclonal antibody that specifically binds to human HMGB1, wherein the human monoclonal antibody (anti-human HMGB1 antibody) comprises a heavy chain CDR1, heavy chain CDR2, and heavy chain CDR3 each consisting of a specific amino acid sequence and a light chain CDR1, light chain CDR2, and light chain CDR3 each consisting of a specific amino acid sequence, is used as an agent for preventing or treating ALS, PD, HD, SCA, aging-related degenerative or neurological disease, brain aging, or diseases associated with brain aging. An antibody in which the light chain complementarity determining region (CDR) 3 of the anti-human HMGB1 antibody has been modified is used.

The present invention relates to a diagnostic composition comprising at least one peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 (VDELERIRRSILPYGDSMDRIEKDR), SEQ ID NO: 2 (GGAGSLGAGGAFGEA), SEQ ID NO: 35 (GPAGPPGHPGPPGPR), SEQ ID NO: 4 (EGLITLTELADSLLS), SEQ ID NO: 5 (EFQYLTGGLIEPQVH), SEQ ID NO: 6 (SSHMLTDTKTGLHFN), SEQ ID NO: 7 (FIPGPPGPPGPPGPR), SEQ ID NO: 8 (INEAIEQGTIDKALV), SEQ ID NO: 9 (AFGEAAGDRGPYGTDI) and SEQ ID NO: 10 (LITLTELADSLLSRL). Furthermore, the present invention relates to an in vitro method for detecting the presence or absence of a disease selected from the group of bullous pemphigoid, Parkinson's disease, and a neurological disorder comprising testing the binding of at least one peptide as identified in any of the preceding claims for binding to autoantibodies obtained from a subject suspected of suffering from one of said diseases.

A neural disease diagnosis system based on space-time attention and dynamic domain adaptation belongs to the technical field of cross-modal medical data adaptive analysis. It solves the technical problem that there is an urgent need for a new system that can simultaneously fuse multi-modal information, model multi-scale space-time features, and have dynamic domain adaptation capability to improve the accuracy and generalization ability of multi-site neural disease intelligent diagnosis. The system comprises: a data preprocessing module for extracting standardized time series of individual brain regions from fMRI time series data; a dual-channel feature encoding network module for obtaining global features through an attention mechanism; a feature fusion and classification module, wherein a main task classifier performs a main task to predict whether a testee has a neural disease, and a domain task classifier performs a domain task to predict the site to which the testee belongs; and a dynamic balance training module for adjusting the dynamic balance of the main task and the domain task through a dynamic balance control strategy.

A method for identifying a cerebral edema or a cerebral microhemorrhage in a subject, the method including providing a sample obtained from the subject, comprising a level of one or more biomarkers, wherein the one or more biomarkers comprises one or more GLX-related GAGs, one or more GLX-related PGs, one or more GLX-related GPs, one or more GLX-related GLs, one or more GLX-related GCs, or one or more fragments thereof, or any combination of the aforementioned biomarkers; measuring or detecting the level of the one or more biomarkers in the sample; comparing the level of the one or more biomarkers measured or detected to a reference level for the one or more biomarkers; and identifying the subject as having a cerebral edema or a cerebral microhemorrhage if the level of the one or more of the biomarkers measured or detected from the sample are different than the reference level for the one or more biomarkers.

This invention relates to 2-amino-4-methylquinazoline compounds, their preparation methods, uses, and pharmaceutical compositions. Specifically, it provides a compound represented by Formula I, which is a phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitor that can be used to prevent and / or treat diseases related to PI3Kδ activity, such as tumors, autoimmune diseases, immunodeficiency diseases, inflammation, kidney diseases, cardiovascular diseases, metabolic / endocrine disorders, or neurological diseases.

The invention belongs to the field of chemical pharmacy. Relates to 4-methylquinazoline derivatives, and a preparation method, a pharmaceutical composition and application thereof. The 4-methylquinazoline derivative is a compound shown in a formula (I) or a pharmaceutically acceptable salt thereof, is a PI3K inhibitor, and can be used for preventing and / or treating diseases related to PI3K activity, such as tumors, autoimmune diseases, kidney diseases, cardiovascular diseases, inflammation, metabolism / endocrine dysfunction or nerve diseases.

This invention relates to compositions for the prevention or treatment of degenerative neurological diseases, comprising a compound that induces the expression of the anti-aging gene klotho as an active ingredient. The compound of this invention, expressed by chemical formula 1, exhibits excellent efficacy in increasing the expression level of the Klotho gene, a gene related to aging, and can be effectively used as a pharmaceutical composition or food composition for the prevention, improvement, or treatment of degenerative neurological diseases.

The present invention relates to a process for the industrial scale preparation of (3β,24S)-25,25,25-trifluoro-3-methyl-26,27-dinorergost-5-ene-3,24-diol, useful in counteracting the progression of highly disabling neurological diseases such as Alzheimer's, Parkinson's, and Huntington's disease, and having the structure shown below: The invention also relates to an improved method for the separation of two epimers that are obtained during the synthesis.

The present invention provides, in part, protein-drug conjugates comprising an anti-transferrin receptor (e.g., human transferrin receptor) antigen-binding protein (e.g., scFv, Fab) conjugated to a molecular cargo (e.g., polynucleotides, liposomes or lipid nanoparticles) for delivery of the molecular cargo to a targeted tissue (e.g., brain or muscle). Methods for treating various diseases or disorders, such as neurological diseases or muscular diseases, with the conjugates are provided.

This invention belongs to the field of pharmaceutical technology and relates to thienopyrimidine derivatives, their preparation methods, uses, and pharmaceutical compositions. The thienopyrimidine derivatives, as shown in formula (I), are phosphatidylinositol 3-kinase δ (PI3Kδ) inhibitors and can be used to prevent and / or treat diseases related to PI3Kδ activity, such as tumors, autoimmune diseases, immunodeficiency diseases, kidney diseases, cardiovascular diseases, inflammation, metabolic / endocrine dysfunction, or neurological diseases.

The invention discloses a nerve disease medicine composition and a preparation method and application thereof, the medicine composition contains active ingredients of edaravone, borneol and blumea balsamifera, and the weight ratio of the borneol and the blumea balsamifera in the three active ingredients is 10%-35%, preferably 15%-25%. According to the pharmaceutical composition disclosed by the invention, in free radical scavenging and ALS pharmacodynamic tests, when the weight ratio of the borneol to the blumea balsamifera in the three active ingredients is 10%-35% and the blumea balsamifera accounts for 0.05%-1.5% of the weight of the borneol, the pharmacodynamic effect is optimal; the anti-inflammatory effect is very good; the L-borneol has low dose dependence on the enhancement effect of the permeability of the blood brain barrier, and the transmembrane transport of the medicine can be obviously promoted within the concentration range of 0.05-1.5%.

This invention belongs to the field of microfluidic organ-on-a-chip technology, and relates to an assemblable multi-cell co-culture brain organ-on-a-chip and its applications. The multi-cell co-culture brain organ-on-a-chip consists of a lower substrate, a middle chip, and an upper chip. The upper chip has one cell culture chamber and eight inlet / outlet ports, while the middle chip has seven cell culture chambers. The six cell culture chambers are arranged in a hexagonal pattern around the central chamber, and adjacent chambers are interconnected through a micro-forestation structure. The lower substrate serves as a supporting base. Compared with existing brain organ-on-a-chips, this chip device can effectively induce and stably generate Lewy bodies, and can reproduce typical pathological features of Parkinson's disease that are difficult to achieve with traditional chips. It is particularly suitable for simulating the blood-brain barrier and co-culture systems of brain parenchymal cells, providing novel device support for the study of Parkinson's disease mechanisms and in vitro drug screening, and has significant application value in the fields of neurological disease model construction and drug development.

The present invention relates to a composition comprising a mixture of molecules, said mixture comprising at least chrysin, pinocembrin and CAPE, for its use in the prevention or treatment of neuroinflammation and / or diseases or disorders associated with neuroinflammation.

The present invention relates to bumetanide derivatives of formula (I) as well as pharmaceutical compositions comprising these compounds for use in the treatment or prevention of neurological diseases / disorders involving Na+—K+-2Cl−—cotransporters (NKCCs), such as stroke, traumatic brain injury (TBI), spinal cord injury (SCI), peripheral nerve injury (PNI), brain edema, or glioma, and particularly for use in the treatment or prevention of stroke. The invention likewise relates to a method of treating or preventing a neurological disease or disorder involving an NKCC, such as stroke, TBI, SCI, PNI, brain edema, or glioma, the method comprising administering a compound of formula (I) to a subject in need thereof.

Disclosed herein are methods of treating diseases or disorders that are mediated by the loss of synaptic connectivity and / or plasticity, such as neurological diseases and disorders, with phenoxy or benzyloxy substituted neuroplastogens.

Disclosed herein are UNC13A antisense oligonucleotides with modified backbone structures. The disclosed UNC13A oligonucleotides reduce mis-spliced UNC13A transcripts and increase full length UNC13A transcripts, thereby imparting therapeutic efficacy against neurological diseases such as amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), or Alzheimer's disease (AD).

The invention relates to an engineered exosome as well as a preparation method and application thereof. According to the invention, an integrated platform technology is developed, composite nanoparticles with specific structures and composition are designed, and an exosome preparation process is developed based on the composite nanoparticles, so that four steps of an engineered exosome production process are expected to be improved at the same time, efficient preparation of the engineered exosome is realized, and the obtained exosome has good stability, can efficiently load drugs, and has good application prospects. The medicine can be applied to treatment of cranial nerve diseases, respiratory system diseases and the like.

This document provides compounds, methods, and compositions for determining whether a patient has a neurological disease or condition, including detecting the presence or cumulative mass of a detectable target protein, such as amyloid-β protein or phosphorylated tau protein, in a patient's tissue or sample. The detection may include contacting the target protein with a compound described herein.

Provided herein are lipid compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive lipid compounds, compositions, or formulations for treating and / or preventing diseases (e.g., genetic disease, proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, metabolic disorder, long-term medical condition, inflammatory disease, autoinflammatory disease, liver disease, lung disease, spleen disease, familial amyloid neuropathy, cardiovascular disease, viral infection, infectious disease, fibrotic condition, or autoimmune disease) in a subject, methods for synthesizing the compounds described herein, and compounds described herein synthesized by the synthetic methods described herein. The compounds are effective carriers for the delivery of an agent such as a polynucleotide (e.g., RNA) to a tissue or cell in a subject (e.g., a liver, lung, or spleen tissue / cell).

Provided herein are antibodies and antigen-binding domains that specifically bind to human CD98 and their use in, for example, transport across the blood brain barrier (BBB). Among others, also provided herein are conjugates comprising these anti-CD98 antibodies and antigen-binding fragments, such as the conjugates with GLP-1R agonists, and their uses in, for example, treating or preventing neurological diseases or disorders and / or metabolic diseases or disorders.

The invention provides novel anti-IL-31RA proteins, antibodies and IL-31RA binding fragments thereof, which inhibit association of IL-31 with IL-31 receptor and are suitable for administration to a human or canine subject. The invention provides novel compositions and methods of treating, alleviating the symptoms of, or preventing, allergic / inflammatory diseases, lung diseases, cardiovascular diseases, cancers, metabolic diseases, neurological diseases, and infectious diseases, comprising administering an effective amount of an anti-IL-31RA protein, antibody, or fragment thereof. The methods and compositions are used to treat or prevent IL-31-related disorders.